tetano
Editor, Senior Moderator
J Immunol
. 2020 Jun 3;ji2000513.
doi: 10.4049/jimmunol.2000513. Online ahead of print.
Inflammasomes and Pyroptosis as Therapeutic Targets for COVID-19
Jeremy K Y Yap[SUP] 1 [/SUP], Miyu Moriyama[SUP] 2 [/SUP], Akiko Iwasaki[SUP] 3 4 5 [/SUP]
Affiliations
Abstract
The inflammatory response to severe acute respiratory syndrome-related coronavirus 2 infection has a direct impact on the clinical outcomes of coronavirus disease 2019 patients. Of the many innate immune pathways that are engaged by severe acute respiratory syndrome-related coronavirus 2, we highlight the importance of the inflammasome pathway. We discuss available pharmaceutical agents that target a critical component of inflammasome activation, signaling leading to cellular pyroptosis, and the downstream cytokines as a promising target for the treatment of severe coronavirus disease 2019-associated diseases.
. 2020 Jun 3;ji2000513.
doi: 10.4049/jimmunol.2000513. Online ahead of print.
Inflammasomes and Pyroptosis as Therapeutic Targets for COVID-19
Jeremy K Y Yap[SUP] 1 [/SUP], Miyu Moriyama[SUP] 2 [/SUP], Akiko Iwasaki[SUP] 3 4 5 [/SUP]
Affiliations
- PMID: 32493814
- DOI: 10.4049/jimmunol.2000513
Abstract
The inflammatory response to severe acute respiratory syndrome-related coronavirus 2 infection has a direct impact on the clinical outcomes of coronavirus disease 2019 patients. Of the many innate immune pathways that are engaged by severe acute respiratory syndrome-related coronavirus 2, we highlight the importance of the inflammasome pathway. We discuss available pharmaceutical agents that target a critical component of inflammasome activation, signaling leading to cellular pyroptosis, and the downstream cytokines as a promising target for the treatment of severe coronavirus disease 2019-associated diseases.